Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease

European Respiratory Journal

Volumn 14, Issue 2, 1999, Pages 347-351

  Gilljam, M ^b   Berning, S E ^a   Peloquin, C A ^a   Strandvik, B ^c   Larsson, L O ^c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

Cystic fibrosis; Mycobacterial disease; Therapeutic drug monitoring

Indexed keywords

14 HYDROXYCLARITHROMYCIN; ANTIMYCOBACTERIAL AGENT; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; OFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FORCED EXPIRATORY VOLUME; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL;

EID: 0032858408     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.14b18.x     Document Type: Article

References (27)

1. Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes DM, eds. Cystic Fibrosis. London, Chapman and Hall, 1995; pp. 1-13.
2. Smith M, Efthimiou J, Hodson M, Batten J. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984; 39: 369-375.
3. Hjelte L, Petrini B, Källenius G, Strandvik B. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990; 45: 397-400.
4. Kilby J, Gilligan P, Yankaskas J, Highsmith W, Edwards L, Knowles M. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102: 70-75.
5. Aitken M, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993; 103: 1096-1099.
6. Kavanagh RE, Unadkat JD, Smith AL. Drug disposition in cystic fibrosis. In: Davies PB, ed. Cystic Fibrosis, Vol. 64. New York, Marcel Dekker, 1993; pp. 91-136.
7. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997; 18: 79-87.
8. Schwachman H, Kulczycki L. Long-term study of one hundred five patients with cystic fibrosis. Am J Dis Child 1958; 96: 6-15.
9. Davidson P. Managing tuberculosis during pregnancy. Lancet 1995; 346: 199-200.
10. Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16: 717-729.
11. Kinney J, Little B, Yolken R, Rosenstein B. Mycobacterum avium complex in a patient with cystic fibrosis: disease versus colonization. Pediatr Infect Dis J 1989; 8: 393-396.
12. Griffith D, Girard W, Wallace R Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am J Respir Dis 1993; 147: 1271-1278.
13. Wallace R Jr, Glassroth J, Griffith D, Olivier N, Cook J, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156 (Suppl. 2): s1-s25.
14. Hjelt K, Højlyng N, Howitz P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994; 26: 569-576.
15. Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. J Clin Microbiol 1997; 35: 2706-2708.
16. Soini H, Viljanen M. Gene amplification in the diagnosis of mycobacterial infections. APMIS 1997; 105: 345-353.
17. Mulherin D, Coffey M, Halloran D, Keogan M, Fitzgerald M. Skin reactivity to atypical mycobacteria in cystic fibrosis. Respir Med 1990; 84: 273-276.
18. Durie PR, Pencharz PB. Cystic fibrosis: nutrition. Br Med Bull 1992; 48: 823-846.
19. van Soolingen D, Hermans P. Epidemiology of tuberculosis by DNA fingerprinting. Eur Respir J 1995; 8: Suppl. 20, 640s-656s.
20. Hedstrom S, Martens M. Antibiotics in pregnancy. Clin Obstet Gynecol 1993; 36: 886-892.
21. Peloquin C, Berning S. Evaluation of the drug interaction between clarithromycin and rifampin. J Infect Dis Pharmacother 1996; 2: 19-35.
22. Sturgill M, Rapp R. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992; 26: 1099-1108.
23. Turner M, McGowan C, Nardell E, Haskal R. Serum drug levels in tuberculosis patients. Am J Respir Crit Care Med 1994; 149: A527.
24. Patel K, Belmonte R, Crowe H. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332: 336-337.
25. Peloquin C, Nitta A, Burman W, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-925.
26. Olivier K, Yankaskas J, Knowles M. Nontuberculous mycobacterial disease in cystic fibrosis. Semin Respir Infect 1996; 11: 272-284.
27. Winter ME. In: Young LY, Koda-Kimble MA. Basic Clinical Pharmacokinetics eds. 2nd Edn. Applied Therapeutics, Washington, Spokane, 1988; pp. 1-14.